Introduction:
Peptide-Oligonucleotide Conjugation Optimization is the systematic tuning of chemistry, reaction conditions, monitoring and purification so that a peptide and an oligonucleotide join into one well-defined, high-yield molecule. At ResolveMass Laboratories Inc., a Canadian analytical CRO/CDMO, our scientists apply this discipline to programs where yield, purity and reproducibility decide whether a candidate can move forward.
Peptide-oligonucleotide conjugates (POCs) are attractive because the peptide can improve cell uptake, tissue targeting or endosomal escape, while the oligonucleotide delivers the therapeutic sequence. They are also among the most difficult conjugates to make. Opposite charges, hydrophobic patches and sensitive functional groups can all reduce yield.
This case study walks through how our team diagnosed a low-yield program, which changes mattered most, and how we confirmed the result analytically. The same approach is relevant to sponsors working with antisense oligonucleotides (ASOs), siRNA and other nucleic acid modalities.
Summary:
Peptide-oligonucleotide conjugation optimization raised the isolated yield of a complex conjugate from roughly 28% to roughly 71% by fixing linker chemistry, aggregation, stoichiometry and purification together. In brief:
- The problem: low yield (~28%), heavy aggregation and a heterogeneous product mixture in a cationic peptide to phosphorothioate oligonucleotide program.
- The root causes: a mismatched ligation chemistry, charge-driven peptide-oligonucleotide aggregation, hydrolysis of the activated linker, and purification losses.
- The fixes: a site-specific, orthogonal linker strategy, tuned buffer and co-solvent conditions, a Design of Experiments (DoE) approach to stoichiometry and pH, in-process LC-MS monitoring, and orthogonal purification.
- The outcome: isolated yield ~28% to ~71%, purity ~78% to >95%, and aggregates below 2%.
- The proof: every claim was verified with high-resolution mass spectrometry (HRMS), ion-pair reversed-phase HPLC (IP-RP-HPLC), size-exclusion chromatography (SEC) and capillary electrophoresis (CE).
Note: This is an anonymized case study. Client identities and sequences are withheld, and values are rounded.
1: Why Is Peptide-Oligonucleotide Conjugation So Difficult?
It is difficult because two very different molecules must react selectively in one pot: a polyanionic oligonucleotide and a peptide that is often cationic, hydrophobic or both. Their opposing properties cause aggregation, side reactions and recovery losses.
| Challenge | Why it lowers yield |
|---|---|
| Charge mismatch | Cationic peptides bind the anionic phosphate backbone and form insoluble complexes |
| Competing reactions | Activated linkers hydrolyze in water before they react with the target |
| Disulfide formation | Free thiols oxidize and cap the peptide before conjugation |
| Solubility gaps | Peptides need organic co-solvent while oligonucleotides need aqueous salt |
| Similar retention | Conjugate, free peptide and free oligonucleotide are hard to separate |
Understanding which of these factors dominates is the first step in any Peptide-Oligonucleotide Conjugation Optimization effort.
2: What Was the Challenge in This Peptide-Oligonucleotide Program?
The sponsor needed a reproducible conjugate of a cysteine-containing, cationic peptide and a modified oligonucleotide, but early batches delivered only about 28% isolated yield. That was far below what the program needed to scale.
The starting materials were:
- Oligonucleotide: a 20-mer antisense sequence with a phosphorothioate backbone and 2′-modified sugars, carrying a 5′-amino linker
- Peptide: an 18-residue cationic peptide with a single cysteine for attachment
- Initial route: a heterobifunctional NHS-maleimide linker, one-pot reaction, preparative reversed-phase purification
The sponsor’s targets were at least 60% isolated yield, at least 90% purity by HPLC, and consistent results from milligram to multi-gram scale. Early batches also showed visible turbidity during the reaction, a sign that aggregation was part of the problem.
3: What Caused the Low Conjugation Yield?
Four overlapping causes explained the loss: linker hydrolysis, peptide oxidation, charge-driven aggregation and purification losses. We isolated each one by running small, controlled experiments with LC-MS readouts rather than changing everything at once.
| Root cause | Evidence we saw | Impact on yield |
|---|---|---|
| NHS ester hydrolysis | Large amounts of unreacted amino-oligonucleotide and hydrolyzed linker by LC-MS | High |
| Peptide disulfide dimers | Dimer mass observed; free thiol content fell before conjugation | Medium |
| Charge-driven aggregation | Turbidity, broad SEC peaks and early-eluting species | High |
| Purification losses | Conjugate co-eluted with free peptide and was cut away with side fractions | Medium |
This evidence-first approach matters. Optimizing the wrong variable can look productive on paper and still leave the real bottleneck in place.
4: How Can Analytical Testing Identify the Root Cause of Low Yield?
Analytical testing shows whether low conjugation yield comes from incomplete coupling, product degradation, unexpected impurities or purification losses. Orthogonal methods give complementary information on molecular mass, chromatographic purity and product identity.
HPLC and UPLC for Reaction Monitoring
HPLC and UPLC can separate the conjugate from residual starting materials when the method gives adequate resolution. Useful measurements include:
- Relative peak areas for reaction monitoring
- Changes in the abundance of unreacted starting materials
- Additional peaks forming during the reaction
- Chromatographic profiles before and after purification
Peak-area percentage should not automatically be read as molar conversion or absolute purity. Peptide and oligonucleotide components absorb UV light differently, so quantitative conversion needs response factors, suitable reference materials and an awareness of detector limits.
LC-MS and HRMS for Molecular Identity
LC-MS and HRMS help confirm whether the expected conjugate formed and identify unexpected species that chromatography alone cannot. They can support investigation of:
- The expected molecular mass of the conjugate
- Residual peptide or oligonucleotide
- Incomplete or unintended conjugation products and linker-related impurities
- Oxidation, hydrolysis and other mass-altering modifications
Oligonucleotide analysis needs careful attention to charge-state distributions, adducts, desalting and deconvolution. A matching mass supports the proposed identity, but it does not by itself establish complete structure, attachment-site specificity or purity.
Orthogonal Characterization
When first results do not explain the problem, additional methods can be selected based on the analytical question:
| Technique | Potential contribution |
|---|---|
| UV spectroscopy | Concentration assessment, where suitable extinction coefficients and validated procedures exist |
| Peptide mapping or amino acid analysis | Complementary information on peptide composition or content |
| Capillary electrophoresis | An additional separation approach for suitable samples |
| Size-exclusion chromatography | Investigation of aggregation or size-related species |
| Stability-indicating chromatography | Changes in product quality during reaction holds and storage |
| NMR spectroscopy | Structural information when sample quantity and complexity permit |
Using several techniques is valuable only when they provide genuinely complementary evidence rather than repeating the same measurement.
5: How Did We Approach Peptide-Oligonucleotide Conjugation Optimization?
We addressed each root cause in sequence: confirm the starting materials, re-select the linker chemistry, control aggregation, optimize conditions with DoE, monitor in process, and purify orthogonally. Each step was verified before the next one began.
Step 1: Confirm Starting-Material Quality
Verifying both components before optimizing prevents you from chasing problems that start upstream. Each should meet appropriate specifications for identity, concentration, purity and functional-group availability.
Common issues include:
- Uncertain starting-material concentration
- Incomplete functionalization of the peptide or oligonucleotide
- Residual salts or synthesis-related impurities
- Peptide oxidation or aggregation
- Oligonucleotide degradation or unintended modifications
- Variability in water content or counter-ion composition
Starting-material variability can make a suitable reaction look inconsistent, so a reliable baseline is essential.
Step 2: Re-Select the Linker and Ligation Chemistry
Switching to a more hydrolysis-tolerant, site-specific route removed the largest source of loss. We replaced the single-pot NHS-maleimide route with a two-stage approach: the oligonucleotide was activated first and purified, then reacted with a freshly reduced peptide. This kept the reactive linker away from water for as little time as possible.
Step 3: Control Charge-Driven Aggregation
Aggregation fell sharply once ionic strength, co-solvent and temperature were tuned together. We screened:
- Salt concentration, to shield opposite charges without precipitating the oligonucleotide
- Organic co-solvent level (such as DMSO or acetonitrile), to keep the peptide in solution
- Peptide addition rate and temperature, to avoid local concentration spikes
Step 4: Optimize Peptide-Oligonucleotide Conjugation Conditions With DoE
A multi-factor DoE found the best balance of pH, peptide excess and time in far fewer runs than one-factor-at-a-time testing. The model showed that a modest peptide excess at mildly acidic to neutral pH beat larger excesses, which had increased aggregation without improving conversion.
Screening ranges must be based on the chemistry, preliminary data and component stability. The table below does not prescribe universal operating conditions.
| Parameter | Potential effect | Evaluation approach |
|---|---|---|
| Reaction pH | Changes functional-group reactivity and stability | Compare chemistry-compatible pH conditions |
| Reagent stoichiometry | Sets availability of reactive partners | Evaluate justified molar ratios |
| Reaction time | Affects conversion and degradation | Collect time-course samples |
| Temperature | Influences kinetics and stability | Compare controlled temperatures |
| Solvent and buffer | Affect solubility and interactions | Screen compatible formulations |
| Addition order and mixing | Influence local concentration and reproducibility | Compare controlled addition and mixing |
| Linker design | Affects accessibility, stability and geometry | Assess alternatives when justified |
A practical DoE sequence looks like this:
- Define the critical quality attributes and measurable responses.
- Identify potentially influential process parameters.
- Run a screening study to find the factors with the greatest impact.
- Evaluate key interactions and optimize the most influential factors.
- Confirm the selected conditions in independent experiments.
- Document the results and define an appropriate operating range.
Responses can include desired-product conversion, crude purity, impurity formation, reproducibility and recovery after purification. Final conditions should be chosen on several criteria, not by maximizing one response at the expense of product quality.
Step 5: Monitor the Reaction by LC-MS
In-process LC-MS let us stop the reaction at peak conversion instead of at a fixed time. Each sample confirmed the conjugate mass and flagged dimers or hydrolysis products early.
Reliable optimization also depends on analytical controls that separate real chemical improvement from analytical variability:
- Individual peptide and oligonucleotide starting materials
- A reaction blank, where appropriate
- A pre-reaction sample and time-course samples
- Suitable product or reference materials, when available
- Samples collected before and after purification
Sample preparation, dilution, desalting and storage should be controlled so they do not introduce misleading differences between experiments.
Step 6: Purify Orthogonally to Protect Recovery
Combining ion-pair reversed-phase and ion-exchange steps recovered more conjugate than a single reversed-phase pass. The first step removed free peptide, and the second separated unreacted oligonucleotide, with fraction cuts guided by mass data rather than UV alone.
6: How Can Purification Improve Final Conjugate Recovery?
Purification optimization increases the amount of acceptable conjugate recovered by balancing impurity removal against product loss. A reaction can reach high conversion and still deliver a disappointing final yield if the conjugate is poorly retained, unstable or hard to separate from related species.
Depending on molecular properties and process needs, options include:
- Reversed-phase chromatography
- Ion-exchange chromatography
- Hydrophilic interaction chromatography, where suitable
- Size-based separation, when the components differ enough in size
- Desalting or buffer exchange to remove salts and small molecules
The chosen method must be compatible with the peptide, oligonucleotide, linker and intended product form.
Reaction Yield Versus Purification Recovery
Three separate measurements show where material is being lost:
| Measurement | What it tells the team |
|---|---|
| Reaction conversion | How much starting material has reacted, based on a suitable analytical definition |
| Crude selectivity or purity | How much of the mixture is the desired product |
| Purification recovery | How much desired product entering purification is recovered afterward |
These are not interchangeable. A process can show good conversion but poor selectivity because of side reactions, or good crude purity but low recovery. A mass balance across reaction, sample preparation, purification and final formulation helps locate the losses.
7: What Results Did Peptide-Oligonucleotide Conjugation Optimization Deliver?
The optimized process more than doubled isolated yield, from about 28% to about 71%, and met every sponsor target. Purity and reproducibility improved at the same time.
| Parameter | Before | After |
|---|---|---|
| Isolated yield | ~28% | ~71% |
| HPLC purity | ~78% | >95% |
| Aggregates (SEC) | ~12% | <2% |
| Unreacted oligonucleotide | ~30% | <3% |
| Batch-to-batch yield spread | Wide | Within ±5% |
The process also held up when scaled up from milligram to multi-gram batches, which is what the sponsor needed for downstream studies.
How Should the Optimized Process Be Evaluated for Scale-Up?
An optimized laboratory reaction should be tested for robustness before transfer to a larger scale, because mixing, reagent addition, heat transfer and material handling all change with volume. Scale-up assessment should consider:
- Consistency of starting-material quality
- Mixing and homogeneity during reagent addition
- Reaction kinetics at the intended working volume
- Product stability during reaction and hold periods
- Chromatographic loading and purification capacity
- Recovery during concentration and buffer exchange
- Batch-to-batch variability and in-process controls with acceptance criteria
A risk-based strategy identifies the parameters most likely to affect critical quality attributes, and targeted experiments then confirm the process stays consistent within its operating range. For pharmaceutical development, documentation should support traceability of materials, analytical results, deviations and process changes. Applicable quality and regulatory expectations depend on the development stage and intended use.
How Was the Conjugate Characterized and Verified?
We used orthogonal analytical methods so that no single technique could hide a problem. Mass spectrometry confirmed identity, while chromatography and electrophoresis confirmed purity and size distribution.
| Method | What it confirmed |
|---|---|
| HRMS (intact mass) | Correct conjugate mass and absence of dimers or truncations |
| IP-RP-HPLC | Purity and separation from free peptide and oligonucleotide |
| SEC | Aggregate and high-molecular-weight species levels |
| Capillary electrophoresis | Charge heterogeneity and length-related impurities |
Methods were documented, traceable and developed in line with the principles of ICH Q2(R2) for analytical procedure validation. Raw data and acceptance criteria were shared with the sponsor so results could be independently reviewed.
What Best Practices Improve Peptide-Oligonucleotide Conjugation Yield?
The most reliable gains come from diagnosing before optimizing, separating activation from conjugation, and measuring everything by mass. These lessons apply to most peptide-oligonucleotide programs:
- Diagnose first. Use LC-MS on small test reactions to find the real loss mechanism.
- Verify starting materials. Functional-group availability and material quality directly affect performance.
- Distinguish conversion from product quality. Consuming starting material does not guarantee the intended conjugate formed.
- Protect the peptide thiol. Reduce freshly and work under conditions that limit oxidation.
- Separate activation and conjugation when the linker hydrolyzes quickly.
- Tune charge interactions. Adjust ionic strength and co-solvent before changing stoichiometry.
- Use DoE. It finds interactions between pH, temperature, stoichiometry and time that single-variable tests miss.
- Measure purification recovery independently, and cut fractions using mass data.
- Confirm reproducibility with independent experiments and documented controls before calling conditions robust.
- Preserve product integrity. The final process must maintain the required structure and stability, not merely maximize yield.
- Plan for scale early. Confirm that mixing and addition rates translate to larger batches.
How Can ResolveMass Laboratories Inc. Support Peptide-Oligonucleotide Programs?
ResolveMass Laboratories Inc. can support peptide-oligonucleotide programs with integrated analytical testing to investigate reaction performance, confirm molecular identity and evaluate impurities. Depending on project requirements and available validated methods, relevant support may include:
- LC-MS and LC-MS/MS analysis for molecular characterization
- HRMS-based investigation of expected and unexpected molecular species
- HPLC or UPLC method development and chromatographic impurity assessment
- Analytical method development, validation, verification or transfer, as appropriate to the project
- Support for investigating discrepancies between expected and observed analytical results
- Analytical data packages that support pharmaceutical development and quality assessment
The right testing plan depends on the peptide and oligonucleotide sequences, conjugation chemistry, linker structure, expected impurities, sample availability and development stage. Specific capabilities, turnaround times and deliverables should be confirmed with the laboratory before project initiation.
Conclusion:
Peptide-Oligonucleotide Conjugation Optimization turns an unpredictable, low-yield reaction into a controlled, scalable process by combining root-cause diagnosis, smarter chemistry, DoE and mass-guided purification. In this program, that approach lifted isolated yield from about 28% to about 71% and brought purity above 95%.
Frequently Asked Questions:
Low conjugation yield can result from steric hindrance, inaccessible reactive groups, unsuitable pH, incorrect reagent stoichiometry, peptide aggregation, oligonucleotide degradation, competing side reactions, or product loss during purification.
Common approaches include thiol–maleimide coupling, disulfide formation, click chemistry, and amide bond formation. The most appropriate chemistry depends on the functional groups, linker design, molecular stability, and intended application.
Linker design influences the accessibility of reactive groups, steric hindrance, molecular flexibility, conjugate stability, and the separation of the peptide and oligonucleotide components. An appropriate linker can improve coupling efficiency without compromising the desired biological properties.
Design of experiments evaluates multiple reaction variables systematically and identifies important interactions between them. It can help determine suitable operating conditions while reducing reliance on repeated one-factor-at-a-time experiments.
Reference
- Venkatesan N, Kim BH. Peptide conjugates of oligonucleotides: synthesis and applications. Chemical reviews. 2006 Sep 13;106(9):3712-61.https://pubs.acs.org/doi/full/10.1021/cr0502448
- Klabenkova K, Fokina A, Stetsenko D. Chemistry of peptide-oligonucleotide conjugates: a review. Molecules. 2021 Sep 6;26(17):5420.https://www.mdpi.com/1420-3049/26/17/5420
- Lu K, Duan QP, Ma L, Zhao DX. Chemical strategies for the synthesis of peptide− oligonucleotide conjugates. Bioconjugate chemistry. 2010 Feb 17;21(2):187-202.https://pubs.acs.org/doi/abs/10.1021/bc900158s
- Carter JD, LaBean TH. Coupling Strategies for the Synthesis of Peptide‐Oligonucleotide Conjugates for Patterned Synthetic Biomineralization. Journal of nucleic acids. 2011;2011(1):926595.https://onlinelibrary.wiley.com/doi/abs/10.4061/2011/926595
- Malinowska AL, Huynh HL, Bose S. Peptide–oligonucleotide conjugation: chemistry and therapeutic applications. Current issues in molecular biology. 2024 Sep 30;46(10):11031-47.https://www.mdpi.com/1467-3045/46/10/655
- Fàbrega C, Aviñó A, Navarro N, Jorge AF, Grijalvo S, Eritja R. Lipid and peptide-oligonucleotide conjugates for therapeutic purposes: from simple hybrids to complex multifunctional assemblies. Pharmaceutics. 2023 Jan 18;15(2):320.https://www.mdpi.com/1999-4923/15/2/320
About the Author
